Dee the result of last similar formation highlighted in the chart.
Trade active
Glenmark Pharma reported better than expected EBITDA and EBITDA margin.· Q1 net profit Rs254cr (up 132% YoY) – expectation Rs144cr,
· Ebitda Rs478cr (up 40% YoY) – expectation Rs372cr,
· EBITDA margin 20.4% vs 14.5% (YoY) – expectation 14.8%
· Income Rs Rs2345cr (up 1% YoY)- expectation Rs2515cr
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.